Odile Burlet‐Schiltz

A cytidine deaminase biodegrader sensitises multiple cancer types to deoxycytidine analogue-based chemotherapies

Abstract Deoxycytidine (dC) analogues are widely used to treat solid tumours and blood cancers. However, their clinical efficacy is often limited by resistance mediated by cytidine deaminase (CDA), which converts these drugs into inactive metabolites. Existing CDA inhibitors have...